<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185900</url>
  </required_header>
  <id_info>
    <org_study_id>76145</org_study_id>
    <nct_id>NCT00185900</nct_id>
  </id_info>
  <brief_title>Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial</brief_title>
  <official_title>Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      To compare intravenous magnesium sulfate to oral nifedipine for acute tocolysis of preterm
      labor
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence</measure>
    <time_frame>48 hours after administration of study medication.</time_frame>
    <description>Uterine quiescence defined by 12 hours of six or fewer contractions per hour and no further cervical change within 48 hours of tocolytic initiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Uterine Quiescence</measure>
    <time_frame>Until delivery, up to 42 weeks of gestation</time_frame>
    <description>Uterine quiescence was defined by 12 hours of six of fewer contractions per hour and no further cervical change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Age at Delivery</measure>
    <time_frame>Until delivery, up to 42 weeks of gestation</time_frame>
    <description>Presented as weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Birth Weight</measure>
    <time_frame>Until delivery, up to 42 weeks of gestation</time_frame>
    <description>Presented as grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Maternal Adverse Effect</measure>
    <time_frame>From study enrollment until discharge from delivery hospital, up to 30 days after delivery.</time_frame>
    <description>A composite of any of the following: chest pain, pulmonary edema, shortness of breath or hypotension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Neonatal Morbidity</measure>
    <time_frame>From delivery until discharge from the hospital, up to 30 days of age</time_frame>
    <description>Defined as any of the following: respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, sepsis or fetal/neonatal death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Obstetric Labor, Premature</condition>
  <arm_group>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preterm labor treatment with Magnesium Sulfate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preterm labor treatment with Nifedipine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.</description>
    <arm_group_label>Magnesium Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.</description>
    <arm_group_label>Nifedipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria::- Uterine contractions and cervical change or ruptured membranes in a
        preterm gestation Exclusion Criteria:- placental abruption, fetal distress, placenta
        previa, maternal medical contraindication to tocolysis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasser Yehia El-Sayed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.greenjournal.org/</url>
    <description>Obstet Gynecol. 2007 Jul;110(1):61-7.</description>
  </link>
  <results_reference>
    <citation>Lyell DJ, Pullen K, Campbell L, Ching S, Druzin ML, Chitkara U, Burrs D, Caughey AB, El-Sayed YY. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor: a randomized controlled trial. Obstet Gynecol. 2007 Jul;110(1):61-7.</citation>
    <PMID>17601897</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>February 13, 2018</results_first_submitted>
  <results_first_submitted_qc>February 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2018</results_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Yasser Yehia El-Sayed</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Magnesium Sulfate</title>
          <description>Preterm labor treatment with Magnesium Sulfate.
Magnesium Sulfate: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.</description>
        </group>
        <group group_id="P2">
          <title>Nifedipine</title>
          <description>Preterm labor treatment with Nifedipine.
Nifedipine: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Magnesium Sulfate</title>
          <description>Preterm labor treatment with Magnesium Sulfate.
Magnesium Sulfate: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.</description>
        </group>
        <group group_id="B2">
          <title>Nifedipine</title>
          <description>Preterm labor treatment with Nifedipine.
Nifedipine: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="192"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="6.8"/>
                    <measurement group_id="B2" value="26.3" spread="6.3"/>
                    <measurement group_id="B3" value="26.5" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence</title>
        <description>Uterine quiescence defined by 12 hours of six or fewer contractions per hour and no further cervical change within 48 hours of tocolytic initiation.</description>
        <time_frame>48 hours after administration of study medication.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate</title>
            <description>Preterm labor treatment with Magnesium Sulfate.
Magnesium Sulfate: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>Preterm labor treatment with Nifedipine.
Nifedipine: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Prevention of Preterm Delivery for 48 Hours With Attainment of Uterine Quiescence</title>
          <description>Uterine quiescence defined by 12 hours of six or fewer contractions per hour and no further cervical change within 48 hours of tocolytic initiation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Uterine Quiescence</title>
        <description>Uterine quiescence was defined by 12 hours of six of fewer contractions per hour and no further cervical change.</description>
        <time_frame>Until delivery, up to 42 weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate</title>
            <description>Preterm labor treatment with Magnesium Sulfate.
Magnesium Sulfate: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>Preterm labor treatment with Nifedipine.
Nifedipine: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Uterine Quiescence</title>
          <description>Uterine quiescence was defined by 12 hours of six of fewer contractions per hour and no further cervical change.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="6.5"/>
                    <measurement group_id="O2" value="6.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Age at Delivery</title>
        <description>Presented as weeks</description>
        <time_frame>Until delivery, up to 42 weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate</title>
            <description>Preterm labor treatment with Magnesium Sulfate.
Magnesium Sulfate: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>Preterm labor treatment with Nifedipine.
Nifedipine: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Age at Delivery</title>
          <description>Presented as weeks</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="3.4"/>
                    <measurement group_id="O2" value="36.0" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Birth Weight</title>
        <description>Presented as grams</description>
        <time_frame>Until delivery, up to 42 weeks of gestation</time_frame>
        <population>Data included twins, so the group totals are greater than seen in the Overall Number of Participants Analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate</title>
            <description>Preterm labor treatment with Magnesium Sulfate.
Magnesium Sulfate: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>Preterm labor treatment with Nifedipine.
Nifedipine: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Birth Weight</title>
          <description>Presented as grams</description>
          <population>Data included twins, so the group totals are greater than seen in the Overall Number of Participants Analyzed</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2550" spread="802"/>
                    <measurement group_id="O2" value="2650" spread="698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Maternal Adverse Effect</title>
        <description>A composite of any of the following: chest pain, pulmonary edema, shortness of breath or hypotension.</description>
        <time_frame>From study enrollment until discharge from delivery hospital, up to 30 days after delivery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate</title>
            <description>Preterm labor treatment with Magnesium Sulfate.
Magnesium Sulfate: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>Preterm labor treatment with Nifedipine.
Nifedipine: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Maternal Adverse Effect</title>
          <description>A composite of any of the following: chest pain, pulmonary edema, shortness of breath or hypotension.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Neonatal Morbidity</title>
        <description>Defined as any of the following: respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, sepsis or fetal/neonatal death.</description>
        <time_frame>From delivery until discharge from the hospital, up to 30 days of age</time_frame>
        <population>Data included twins, so the group totals are greater than seen in the Overall Number of Participants Analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Magnesium Sulfate</title>
            <description>Preterm labor treatment with Magnesium Sulfate.
Magnesium Sulfate: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine</title>
            <description>Preterm labor treatment with Nifedipine.
Nifedipine: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Neonatal Morbidity</title>
          <description>Defined as any of the following: respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, sepsis or fetal/neonatal death.</description>
          <population>Data included twins, so the group totals are greater than seen in the Overall Number of Participants Analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study enrollment until discharge from the delivery hospital, up to 30 days after delivery.</time_frame>
      <desc>Adverse events were assessed by patient interview from a list of adverse effects and chart review.</desc>
      <group_list>
        <group group_id="E1">
          <title>Magnesium Sulfate</title>
          <description>Preterm labor treatment with Magnesium Sulfate.
Magnesium Sulfate: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.</description>
        </group>
        <group group_id="E2">
          <title>Nifedipine</title>
          <description>Preterm labor treatment with Nifedipine.
Nifedipine: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Double vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anna Girsen</name_or_title>
      <organization>Stanford University</organization>
      <phone>(650) 725-5720</phone>
      <email>agirsen@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

